Early, Late-Stage, and Metastatic Prostate Cancer Treatment
Targeted Prostate Cancer Treatment Options to Help Patients Outperform
Standardized Treatment Models
An early diagnosis and subsequent prostate gland removal may not be enough to prevent the cancer from recurring as an
advanced prostate cancer, a few months or years later. At Envita Medical Centers, a world-class integrative center for
Precision Oncology, we have been treating late-stage and complicated cancers for over 25 years using the latest in
medical research and technology to give our patients a greater chance to respond to care.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Our revolutionary new treatments provide alternatives to invasive surgeries which can be damaging to the immune
system
and potentially lead to further cancer spread. Envita’s powerful and personalized combinations of leading-edge
conventional treatments and advanced natural therapies have proved beneficial for patients of all stages of disease.
Even those with stage IV metastatic castration-resistant prostate cancer (mCRPC) or those who had been sent to hospice
by other well-established cancer centers have benefitted from our treatments and are leading healthy, disease-free
lives
today.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
You may ask yourself, “How can Envita be so successful where these highly regarded centers have failed?”
The answer is simple, our personalized precision oncology approach attempts to overcome treatment challenges caused
by
standard medicine. The standard approach does not properly account for continuing genetic mutations in cancer, which
is
why early treatments can be incomplete causing the cancer to spread to nearby lymph nodes and other distant parts of
the
body as well.
Cancer is a disease of genetic mutations, messaging, and immunity, not of tissue or tumor type and staging
patterns.
Genetics vary from person to person, which highlights the need for personalization in cancer care.
In our clinical experience, the lack of a personalized treatment plan can make many patients experience disease
relapse
or metastasis, after a temporary remission when pursuing standardized treatments.
Personalized Precision Oncology Helps Overcome Standard Treatment Challenges
Treatment of prostate cancer can be challenging because the standard NCCN (National Comprehensive Cancer Network)
guideline protocols may involve a risk of undertreatment or overtreatment, which can have devastating effects. Almost
all major cancer institutions follow the NCCN guidelines to treat prostate cancer, based on its staging, which depends
upon certain factors such as the PSA (Prostate Specific Antigen) levels, Gleason score, and extent of spread. These
factors help in categorizing patients into low, intermediate, or high-risk groups which determine whether they need
active surveillance or aggressive treatment.
However, in our clinical opinion, analyzing these factors alone may not be an accurate guide to precision-targeted
treatments. The absence of precision-targeted treatments in standard treatment protocols can lead to metastatic
disease,
despite early diagnosis and prostate gland removal via surgeries like radical prostatectomy. Though the prostate is
removed, the micro metastatic cancer cells may be sitting dormant in your blood stream for years before manifesting
with
symptoms, such as bone pain, back pain, blood in urine, and elevated PSA levels.
Prostate cancer survival rates drop dramatically if the cancer metastasizes, pointing to the need for
precision-targeted
treatments to decrease the chances of cancer spread. Medical studies show how various
chemotherapeutic drugs and
radiation therapies may allow aggressive prostate cancer cells to gain
advantageous mutations rendering them resistant to treatment.
To address these challenges of overtreatment and sometimes undertreatment in
standard cancer care facilities, we use
precision oncology which helps in identifying the key cancer drivers of each patient and the most appropriate
anti-cancer medicines to treat them.
The following reasons explain why and how Envita’s Personalized
Precision Oncology may help in overcoming standard
treatment challenges:
The NCCN guidelines do not allow access to precision oncology for all patients, but at Envita, with our unique and
personalized precision approach, we aim to identify early signs of micro metastases and proactively treat the
cancer
even before it manifests symptoms.
Personalized precision oncology improves the chances of response in late-stage prostate cancer patients, while in
early-stage, it helps reduce the likelihood of subsequent recurrence or metastasis.
The one-size-fits-all protocols are derived from large sample clinical trials, which is why they may be effective
for
some, but not all prostate cancer patients, despite having the same type and stage of the disease.
These standard treatment protocols may not be enough to target all the distinct cancer expressions of each
individual
patient, leading to a recurrence or metastatic spread of the disease as the cancer turns resistant to treatment.
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
How and Why Does Cancer Become Resistant to Standard Treatment?
Prostate cancer becomes resistant to treatment when patients fail to respond to hormone therapy, radiation, and
multiple
rounds of untargeted chemotherapy. In certain cases, these maximum therapeutic doses of untargeted chemo
inundate the
cancer cells, triggering their ability to pump out some of the anti-cancer medicines. Chemotherapeutic drug
resistance
lowers the cancer cells’ medicine intake capabilities, rendering treatment ineffective. High doses of untargeted
chemotherapy not only trigger aggressive mutations, but they can also weaken the overall immune system, further
debilitating the body’s ability to fight cancer. Approximately
90%
of cancer deaths in patients are linked to
chemotherapeutic drug resistance, and this is the first thing we work to
overcome with Envita’s unique algorithm.
Cancer Cell Pumping Out Untargeted Chemotherapy Drugs
Envita’s Unique New Treatments for Prostate Cancer
To reduce chances of recurrence or metastasis, Envita personalizes a unique medical blueprint for each individual
patient based on the N of 1 model of treatment, which allows us to modify the course of treatment as needed for
mitigating risks of
undertreatment
or overtreatment, leading to optimum results.
Medical studies show overtreatment and
undertreatment are clinical challenges in prostate cancer treatment. Overtreatment creates an unnecessary
burden for many patients
causing other health complications due to medicine toxicity, while undertreatment remains a common problem leading
to recurrence or metastasis.
In our clinical opinion, the standardized approach to prostate cancer is limited to managing the disease, without
progressing towards long-term results of a holistic recovery. To counter this nearsighted approach, Envita focuses on
a
four-pillared personalized precision oncology treatment algorithm, with the goal of improving patients’ quality of
life,
increasing longevity, and reducing toxicity.
Step 1
Genomic Identification Dives Deep Into Your Specific Cancer
A key factor in prostate cancer treatment includes diving deep into your specific cancer to treat the causes driving
the
disease, an often-ignored facet in standard NCCN guideline treatments. The majority of the patients following these
one-size-fits-all protocols do not get access to genomic testing, which is a part of precision oncology.
At Envita, Every Patient’s Entire Treatment Plan Is Based on Our Detailed Precision Algorithms!
Less
than 20% of cancer patients get access to precision oncology, and the limited few who do get precision care,
receive a watered-down version of Envita’s detailed precision
algorithm. At Envita, we not only run in-depth genomic testing for all our patients, but our detailed precision
algorithm analyses many more parameters than standard oncology precision testing to identify and treat each patient’s
unique cancer drivers.
Envita’s Detailed Precision Algorithm Decodes Patient-Specific Cancer Drivers to Help in the
Journey Towards Remission.
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Our in-depth genomic identification helps determine the genetic and epigenetic changes at the cellular and molecular
level, which are directly linked to the cause and spread of each patient’s individual prostate cancer. The majority of
prostate cancer patients develop bone metastases, which may be challenging to evaluate initially, but medical studies
show how improving access and implementation of genomic testing will be critical
to optimizing access to better therapies.
Decoding the genetic and epigenetic causes, which may be triggered by age, race, hereditary, environmental, or
lifestyle
factors, paves the way for a comprehensive treatment plan, designed to attack your specific prostate
cancer. There has
been increased reporting of certain genes, such as the BRCA genes, being connected with prostate
cancer and it is estimated that
men with a mutated BRCA 2 gene are seven times more
likely to develop prostate cancer than the general population. Our detailed genomic overview identifies and
analyses these changes and numerous other genetic mutations to treat the root cause of your prostate cancer, and
aid in
sustained progression against the disease.
If these genetic and epigenetic factors are not addressed, a crucial facet of
your prostate cancer treatment remains
overlooked. Envita Medical Centers is one of the top clinics in the nation for treating not only your cancer,
but its
root causes as well. By treating the genetic and epigenetic influences of your disease, we aim to
precision-target your
cancer and put you on the path towards remission.
Immunotherapy can be effective against prostate cancer treatment, provided they include new therapies beyond vaccine therapies and
checkpoint blockades. At Envita, we have been instrumental in combining different types of
advanced immunotherapies moving beyond the scope of PD-1, PD-L1, or CTLA-4 inhibitors and other smart drugs.
Advanced Immunotherapy for Prostate Cancer
Studies indicate how immunotherapy can be optimized in prostate cancer treatment with combination
therapies which can change the “cold” prostate cancer tumor microenvironment to immunologically “hot” by
driving T cells to the
tumor, which is exactly what we are already doing here at Envita.
In our clinical opinion, including immunotherapy in early-stage cancer treatment limits chances of metastasis,
because
immunotherapy aims to equip your body to better tackle the cancer.
To establish actionable chemo and immuno targets, we use Envita’s Ultra Analytes Liquid Biopsy, which analyses the
Circulating Tumor Cells (CTCs) free flowing in your bloodstream. CTCs are small particles of a growing tumor,
which
break away and enter your blood stream, spreading the cancer to other parts of your body.
Detailed investigation of these CTCs helps us examine the most recent mutations, allowing us to proactively treat
the
cancer in its trajectory, as opposed to treating where it has been.
Our liquid biopsy overcomes the challenges of a traditional tissue biopsy, which is invasive,
difficult, and
may
contain
outdated data, leading to poor treatment selection. Certain aggressive prostate cancers mutate fast, which is
why
basing
your treatment on an old tissue biopsy, usually performed during initial cancer diagnosis, may be limiting in
its
scope.
From our experience, no clinic in the nation tests like we do, which is why we identify many more cancer biomarkers
to
guide treatment for your unique cancer. Biomarkers refer to the proteins, genes, and other molecules which influence
your specific prostate cancer’s growth and proliferation. Precision-targeting your specific cancer biomarkers may help
in effectively striking at the root of the disease.
Our unique approach to testing goes beyond establishing actionable targets, as it also provides information on
toxins,
infections, and other harmful agents that could be restricting treatment efficacy. This detailed data allows us to
personalize your treatment, including immunotherapy options, which harness your body’s innate ability to identify and
kill cancer cells.
A healthy immune system can kill thousands of cancerous and precancerous cells daily, but it is unable to execute
this
function when it has been weakened due to a multitude of reasons. At Envita, we intend to reactivate the immune system
to suit your specific prostate cancer expressions and its ecosystem.
Personalized Drug Design Bridges Gaps in Treatment
At Envita, your prostate cancer treatment is not limited by the scope of anti-cancer medicines available on
the market,
as we take personalization to the next level by custom-building medicines at our in-house pharmacy for each
individual
patient. Despite having the same type and stage of prostate cancer, each patient has different biomarkers, and
our
extensive testing helps pinpoint the medications and natural agents best suited for treating these biomarkers,
which
make every cancer unique.
Current medications existing on the market may not cover all the biomarkers of each
individual patient, revealed via our
detailed testing. We help bridge the gap in treatment, by affecting the cancer biomarkers with our
custom-designed
adjuvant medicines.
In our clinical opinion, a combination of FDA approved drugs, repurposed drugs, and custom-compounded adjuvants work
in
tandem to attack your prostate cancer, as well as bolster your immune system. The custom compounded adjuvants include
advanced phytotherapeutic drugs comprising plant extracts and herbs. You may not be aware but many of the current
oncology drugs are based on phytotherapeutics, which makes plant-based drugs excellent adjuvants for cancer treatment.
At Envita, our pharmacists compound these adjuvants from scratch to suit the unique biomarkers of each individual
prostate cancer patient. They also adjust the dose of FDA approved and repurposed drugs, for each individual patient,
depending on their rate of metabolism. Every patient metabolizes at a different rate, making drug dosage a crucial
part
of cancer treatment to optimize medicine efficacy and reduce its toxicity.
Precision Deployment of New Treatments Improves Outcomes
Envita’s proprietary new treatments include targeted precision-deployment procedures for delivering customized
anti-cancer medications, which not only debulk tumors, but also reactivate your immune system. The mode of precision
deployment is determined based on each patient’s unique cancer expressions and the site of their tumors.
We use intravenous or interventional radiology procedures to increase the bioavailability of our customized
anti-cancer
medicines, enabling them to better target the cancer without impacting the surrounding healthy cells. Our medicines
and
procedures reduce chances of side effects such as fatigue, pain in rectum region, erectile dysfunction, or any other
problems in the area of urology, commonly seen with standard hormone therapy, radiation treatments, and maximum-dose
untargeted chemotherapy.
Patients may need any one or a combination of precision deployment mechanisms to effectively target their unique
prostate cancer. Some of the commonly used treatments are:
Hormone Therapy also called Androgen Deprivation Therapy (ADT)
Hormone therapy is used to control the production or block the impact of male hormones, called androgens, on the
prostate cancer cells. However standard hormone therapy may lead to side effects such as hot flashes, weight-gain,
dizziness, and osteoporosis, often diagnosed through a bone scan. To avoid these side effects, we always use
appropriate
levels of immunotherapy as a follow-up to hormone therapy.
There are several types of hormone therapy to lower testosterone levels and other androgens, produced by the
testicles,
adrenal glands, and even the prostate cancer cells. Some of the different types of hormone therapy include:
Orchiectomy, which is the surgical removal of testicles
Luteinizing hormone releasing hormone (LHRH) agonists and antagonists
Anti-androgens or androgen receptor antagonists
We also use different proprietary procedures to heal your bones and relieve you from pain, in case your bone density
is
affected by hormone therapy prior to starting treatment at Envita.
CIPI™ (Chemo Immuno Precision Injections)
CIPI™ is our proprietary interventional radiology procedure, designed to target inoperable and fibrous tumors,
deactivate them, and produce a full body systemic effect with the goal of remission. As part of this procedure,
genetically targeted chemo and immuno agents are directly deployed to the tumor site via a tiny catheter, thinner than
a
strand of hair. Direct deployment enhances medicine impact and seals the tumor’s blood supply with radionuclide beads,
destroying it and triggering antigen release which trains your immune system to identify and kill cancer elsewhere in
the body.
This unique form of tumor chemoembolization goes beyond standard targeted therapies, chemotherapies, or radiation
therapies because it uses genetically typed anti-cancer medicines, which are likely to be most effective for your
specific prostate cancer. It produces minimal side effects as the powerful dose of customized medications are deployed
directly to the tumor, reducing chances of damage to the adjoining healthy cells. CIPI™ has the potential to
revolutionize the treatment of late-stage prostate cancer by treating common sites of metastasis, including bone,
kidney, pancreas, spleen, or any other organ.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
GTFC™ is our form of low dose
chemotherapy which increases the mechanisms of action against your unique prostate cancer cells, while
potentially decreasing
medication related side-effects. The findings of your detailed genomic analysis take the guesswork out of your
treatment
as it guides us to the chemo drugs with the highest potential of response to your specific prostate cancer
biomarkers.
This information shapes a precision-targeted treatment procedure, which combines customized immuno agents to
optimize
benefits for the patient.
As compared to standard untargeted chemotherapy, GTFC™ reduces chances of
drug
resistance due to the low dose of the
chemo drugs as well as the chemo selection being based off your unique genetic targets. Overcoming the challenge
of drug
resistance in your prostate cancer treatment pushes you forward towards the goal of a long-term remission.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Our expert medical team comprising oncologists, interventional radiologists, researchers, and pharmacists,
collaborate
to offer a different approach to your prostate cancer treatment. They have undergone extensive training to adapt to
our
unique personalized precision oncology approach. We combine the latest in research-based naturopathic and conventional
treatment options from around the world, not just the United States. If you or a loved one is suffering from prostate
cancer or any other form of cancer, please contact us at: 866-830-4576. May God bless you on your journey to healing.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
